Overview

My disease-specific focus is neuroblastoma, the most common extra-cranial solid tumor of childhood. I am interested in older children and adolescents with neuroblastoma, who have more indolent disease but ultimately poor outcomes, and children with central nervous system involvement. Utilization of International Neuroblastoma Risk Group (INRG) data on more than 8,000 children has allowed me to study these rare subgroups and to determine if accepted prognostic factors and treatment approaches are applicable to them.

I also study late effects of cancer and its treatment in survivors of childhood, adolescent and young adult cancer. I am currently involved in a project that will determine if survivors are at increased risk for using prescription mental health drugs, compared to their peers.

Finally, I am interested in developing early phase clinical trials in pediatric oncology to help facilitate the rapid transition of new targeted drug therapies from the lab to the patient.

Publications

Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma
Journal of Pediatric Hematology/Oncology
Alexandra E. Foran, Helen R. Nadel, Anna F. Lee, Kerry J. Savage, Rebecca J. Deyell
DOI: 10.1097/mph.0000000000000703
07/2017

Optimization of liposomal topotecan for use in treating neuroblastoma
Cancer Medicine
Lina Chernov, Rebecca J. Deyell, Malathi Anantha, Nancy Dos Santos, Roger Gilabert-Oriol, Marcel B. Bally
DOI: 10.1002/cam4.1083
05/2017

ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma.
Marr KC, Connors JM, Savage KJ, Goddard KJ, Deyell RJ
DOI: 10.1093/annonc/mdx005
PubMed: 28327925
04/2017

ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
Alassiri AH, Ali RH, Shen Y, Lum A, Strahlendorf C, Deyell R, Rassekh R, Sorensen PH, Laskin J, Marra M, Yip S, Lee CH, Ng TL
DOI: 10.1097/pas.0000000000000677
PubMed: 27259007
08/2016

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.
Cold Spring Harbor Molecular Case Studies
DOI: 10.1101/mcs.a000570
PubMed: 27148575
10/2015

Molecular oncology of neuroblastoma
Molecular Oncology
Vandana Batra and Rebecca J. Deyell and John M. Maris
DOI: 10.1017/cbo9781139046947.060
02/2015

Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
Görges M, West N, Deyell R, Winton P, Cheung W, Lauder G
DOI: 10.1002/pbc.25197
PubMed: 25263424
01/2015

Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK
DOI: 10.1002/pbc.24777
PubMed: 24038992
04/2014

Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia.
Tutelman PR, Aubert G, Milner RA, Dalal BI, Schultz KR, Deyell RJ
DOI: 10.1111/bjh.12656
PubMed: 24236830
03/2014

Antidepressant use among survivors of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program.
Pediatric Blood & Cancer
DOI: 10.1002/pbc.24446
PubMed: 23281214
05/2013

Antidepressant use among survivors of childhood, adolescent, and young adult cancer: Letter to the editor responseLetter to the Editor
Pediatric Blood & Cancer
Rebecca J. Deyell, Maria Lorenzi, John J. Spinelli, Mary L. McBride
DOI: 10.1002/pbc.24885
2013

Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia.
Deyell RJ, Shereck EB, Milner RA, Schultz KR
DOI: 10.3109/08880018.2011.568043
PubMed: 21707222
09/2011

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.
Shereck EB, Deyell RJ, Kurre P
DOI: 10.3324/haematol.2011.044917
PubMed: 21632841
06/2011

Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.
Deyell RJ, Attiyeh EF
DOI: 10.1016/j.cancergen.2011.03.001
PubMed: 21504710
03/2011

Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity hemoglobin variant, hemoglobin Titusville.
Deyell R, Jackson S, Spier S, Le D, Poon MC
DOI: 10.1097/01.mph.0000200685.33291.0a
PubMed: 16462584
02/2006

Research

Prevalence and Predictors of Antidepressant Users among Survivors of Childhood, Adolescent and Young Adult (AYA) Cancer
Five year survivors of childhood and AYA cancer are at risk for many chronic and late-occurring medical conditions including second malignancies and late mortality. They may also be at risk for adversely affected mental health status, although the psychological sequelae of cancer and its therapy remain poorly defined. Through the Childhood, Adolescent and Young Adult Cancer Survivors (CAYACS) research program, we utilize database linkage technology to determine if cancer survivors have an increased likelihood of being antidepressant medication users, compared to an age and gender-matched general population comparison group. We also evaluate which cancer diagnoses and treatment modalities are predictive of requiring prescription antidepressant medications among survivors.

Neuroblastoma in Older Children, Adolescents and Young Adults
Neuroblastoma is the most common extra-cranial solid tumor of childhood and accounts for 10% of pediatric cancer mortality. Its incidence peaks in infancy, with a median age at diagnosis of 17 months. Older children and adolescents with neuroblastoma are rare and typically have an indolent disease course but ultimately poor survival outcomes. In this study, we utilize data from the International Neuroblastoma Risk Group (INRG) on 8,800 children with neuroblastoma to determine if there is an optimal age cut-off greater than 18 months that defines this group and to define the clinical and biological predictors of overall and event-free survival. We also determine whether currently accepted treatment approaches for high-risk neuroblastoma are effective for these patients.

Grants

Clinician Investigator Program, University of British Columbia, 2009-2011

Honours & Awards

John Snow Prize, Epidemiologic methods, University of British Columbia, November 2010

Laura MacRae Subspecialty Resident Award, BC Children’s Hospital, 2010

Research Group Members

Danielle Cohen, Undergraduate Student